Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FITFIX FOR FRAIL
2024-520433-76-00Phase 2Authorised
- Sponsor
- European Myeloma Network
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of daratumumab, teclistamab and talquetamab in multiple myeloma (MM) (2 cohorts), sponsored by European Myeloma Network. Primary endpoint: Progression-free survival at 18 months. Planned start Jan 2026; status: authorised.
02
Drugs
daratumumabteclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-520433-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520433-76-00.